Open Payments

Yale-New Haven Hospital

Type
Teaching hospital
Where
New Haven, CT
Medicare CCN
070022
Received
$2,960,627 in 234 records, 2025 ($269,573 general, $2,691,054 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment61$269,573
2025Research payment173$2,691,054

By company

CompanyRecordsAmountYears
ABBVIE INC.4$746,0582025
Boston Scientific Corporation2$410,0002025
Novartis Pharmaceuticals Corporation9$375,5702025
E.R. Squibb & Sons, L.L.C.6$270,5492025
Siemens Medical Solutions USA, Inc.5$207,3382025
Karyopharm Therapeutics Inc.84$165,4412025
PFIZER INC.10$140,5952025
Merck Sharp & Dohme LLC1$120,3132025
ARGENX US, INC.2$89,2392025
National Marrow Donor Program5$73,0302025
Stryker Corporation35$57,2812025
Diagnostica Stago, Inc1$47,3742025
GE HEALTHCARE2$42,9402025
Verastem, Inc.2$23,0122025
TransMedics, Inc.3$21,0892025
MED-EL Corporation1$18,1802025
Shockwave Medical, Inc9$18,0672025
Hologic Sales and Service, LLC1$15,0632025
Genentech USA, Inc.1$15,0002025
BioXcel Therapeutics, Inc.1$14,6212025
HISTOSONICS, INC.1$12,8452025
KLS-Martin L.P.2$10,2402025
ARRAY BIOPHARMA INC1$10,0002025
Incyte Corporation2$10,0002025
Olympus America Inc.3$8,0002025
Eli Lilly and Company1$5,2992025
Eisai Inc.2$5,1252025
BeiGene USA, Inc.1$5,0002025
SERVIER PHARMACEUTICALS LLC1$5,0002025
Medical Device Business Services, Inc.2$4,5202025
Alexion Pharmaceuticals, Inc.13$4,1162025
Abbott Laboratories10$3,5532025
Ambu Inc.1$3,0952025
Luminex Corporation1$2,4242025
Alnylam Pharmaceuticals Inc.6$3362025
Zimmer Biomet Holdings, Inc.1$1082025
Becton, Dickinson and Company1$1002025
Regeneron Pharmaceuticals, Inc.1$1002025

By nature of payment

NatureRecordsAmount
Research payment173$2,691,054
Compensation for services other than consulting, including serving as faculty or as a speaker at a v23$127,380
Grant9$49,879
Long term medical supply or device loan4$37,241
Space rental or facility fees (teaching hospital only)13$28,553
Debt forgiveness6$18,744
Education2$5,125
Honoraria1$2,424
Charitable Contribution3$225

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Merck Sharp & Dohme LLC$120,313Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYSTUDY NAME#A phase II study of NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell2025
2025-12-31Stryker Corporation$2,133Long term medical supply or device loanIn-kind items and servicesGYNNIE Device, PATIENT HANDLING - PH2025
2025-12-31Stryker Corporation$1,864Long term medical supply or device loanIn-kind items and servicesNA Device, PATIENT HANDLING - PH2025
2025-12-31Siemens Medical Solutions USA, Inc.$398Research paymentIn-kind items and servicesBiograph mCT X-4R Device, MI - Nuclear Medicine (incl. PETNET & MIBR)Software License Yale Myocardial Blood Flow Imaging2025
2025-12-31Alnylam Pharmaceuticals Inc.$48Research paymentIn-kind items and servicesA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-12-22ABBVIE INC.$203,470Research paymentIn-kind items and servicesELAHERE Drug, ONCOLOGYA phase II evaluation of the safety and efficacy of mirvetuximab soravtansine (IMGN853) in women with folate receptor po2025
2025-12-19Olympus America Inc.$1,000Debt forgivenessIn-kind items and services2025
2025-12-18Hologic Sales and Service, LLC$15,063Long term medical supply or device loanIn-kind items and servicesSECURVIEW DIAGNOSTIC WORKSTATION Device, Breast and Skeletal Health2025
2025-12-17Alnylam Pharmaceuticals Inc.$95Research paymentIn-kind items and servicesA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-12-17Alnylam Pharmaceuticals Inc.$25Research paymentIn-kind items and servicesA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-12-15Regeneron Pharmaceuticals, Inc.$100Charitable ContributionCash or cash equivalent2025
2025-12-12Shockwave Medical, Inc$1,910Research paymentCash or cash equivalentEfficacy of the COronary SInus Reducer in Patients With Refractory Angina II2025
2025-12-12Novartis Pharmaceuticals Corporation$780Research paymentCash or cash equivalentKISQALI Drug, OncologyRibociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence2025
2025-12-05Verastem, Inc.$7,002Research paymentCash or cash equivalentVSTM-1004892025
2025-12-05Shockwave Medical, Inc$3,461Research paymentCash or cash equivalentEquity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease2025
2025-12-04Abbott Laboratories$50Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-12-03Karyopharm Therapeutics Inc.$6,701Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-12-03Karyopharm Therapeutics Inc.$4,236Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-12-03Karyopharm Therapeutics Inc.$2,399Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-12-03Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-12-03Karyopharm Therapeutics Inc.$972Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-12-03Karyopharm Therapeutics Inc.$716Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-12-03Karyopharm Therapeutics Inc.$473Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-12-03Karyopharm Therapeutics Inc.$400Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-12-03Karyopharm Therapeutics Inc.$254Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-27Becton, Dickinson and Company$100Charitable ContributionCash or cash equivalent2025
2025-11-25Abbott Laboratories$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentFREESTYLE LIBRE 3 Device, Diabetes Care2025
2025-11-20ABBVIE INC.$203,470Research paymentIn-kind items and servicesELAHERE Drug, ONCOLOGYA phase II evaluation of the safety and efficacy of mirvetuximab soravtansine (IMGN853) in women with folate receptor po2025
2025-11-20Boston Scientific Corporation$105,000Research paymentCash or cash equivalentFARAPULSE Device, FARAPULSE_RMConcomitant Atrial Fibrillation Ablation and Left Atrial Appendage Occlusion in Real-World Practice2025
2025-11-20Abbott Laboratories$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentFREESTYLE LIBRE 3 Device, Diabetes Care2025
2025-11-19Alnylam Pharmaceuticals Inc.$95Research paymentIn-kind items and servicesA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-11-19Alnylam Pharmaceuticals Inc.$25Research paymentIn-kind items and servicesA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-11-12Verastem, Inc.$16,010Research paymentCash or cash equivalentVSTM-1004892025
2025-11-05Karyopharm Therapeutics Inc.$17,716Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-05Karyopharm Therapeutics Inc.$4,236Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-05Karyopharm Therapeutics Inc.$2,399Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-05Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-05Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-05Karyopharm Therapeutics Inc.$1,625Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-05Karyopharm Therapeutics Inc.$716Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-05Karyopharm Therapeutics Inc.$473Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-05Karyopharm Therapeutics Inc.$400Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-05Karyopharm Therapeutics Inc.$400Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-05Karyopharm Therapeutics Inc.$228Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-11-04Abbott Laboratories$50Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-11-04Abbott Laboratories$50Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-10-30PFIZER INC.$2,584Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-10-28Alnylam Pharmaceuticals Inc.$48Research paymentIn-kind items and servicesA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-27Olympus America Inc.$6,000Debt forgivenessIn-kind items and services2025
2025-10-27Medical Device Business Services, Inc.$2,260GrantCash or cash equivalent2025
2025-10-27E.R. Squibb & Sons, L.L.C.$1,449Research paymentCash or cash equivalentPhase III OLE of KarXT in Acute Bipolar_BALSAM32025
2025-10-27Olympus America Inc.$1,000Debt forgivenessIn-kind items and services2025
2025-10-22Alexion Pharmaceuticals, Inc.$113Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-10-20Shockwave Medical, Inc$1,910Research paymentCash or cash equivalentEfficacy of the COronary SInus Reducer in Patients With Refractory Angina II2025
2025-10-17National Marrow Donor Program$17,160Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-10-16Boston Scientific Corporation$305,000Research paymentCash or cash equivalentFARAPULSE Device, FARAPULSE_RMConcomitant Atrial Fibrillation Ablation and Left Atrial Appendage Occlusion in Real-World Practice2025
2025-10-13ABBVIE INC.$203,470Research paymentIn-kind items and servicesELAHERE Drug, ONCOLOGYA phase II evaluation of the safety and efficacy of mirvetuximab soravtansine (IMGN853) in women with folate receptor po2025
2025-10-10National Marrow Donor Program$2,325Research paymentCash or cash equivalent1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy fo2025
2025-10-09Novartis Pharmaceuticals Corporation$141,482Research paymentIn-kind items and servicesKISQALI Drug, OncologyA Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patients Selection for Moderate to Hig2025
2025-10-08Novartis Pharmaceuticals Corporation$394Research paymentIn-kind items and servicesA Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety an2025
2025-10-02Karyopharm Therapeutics Inc.$2,856Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$2,673Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$2,399Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$2,017Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$2,017Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$750Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$750Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$473Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$473Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$473Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$473Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$473Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-10-02Karyopharm Therapeutics Inc.$400Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-09-17SERVIER PHARMACEUTICALS LLC$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-09-12Shockwave Medical, Inc$2,884Research paymentCash or cash equivalentEquity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease2025
2025-09-12Shockwave Medical, Inc$2,140Research paymentCash or cash equivalentEquity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease2025
2025-09-08Abbott Laboratories$139Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-09-08Abbott Laboratories$50Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-09-04Siemens Medical Solutions USA, Inc.$11,756GrantIn-kind items and services2025
2025-09-04Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-09-04Karyopharm Therapeutics Inc.$400Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-08-27GE HEALTHCARE$1,500Research paymentCash or cash equivalentPoint of Care Lung Ultrasound Examination in Patients with Shortness of Breath2025
2025-08-04Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-08-04Karyopharm Therapeutics Inc.$400Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-08-01PFIZER INC.$51,453Research paymentCash or cash equivalentPRE CLINICAL2025
2025-07-23ARGENX US, INC.$49,532Research paymentCash or cash equivalent2025
2025-07-23ARGENX US, INC.$39,707Research paymentCash or cash equivalent2025
2025-07-23National Marrow Donor Program$17,435Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-07-17Stryker Corporation$1,800Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PEERLESS II STUDY2025
2025-07-17TransMedics, Inc.$1,200Research paymentCash or cash equivalentOrgan Care System Device, DeviceOCSHEART-OHP-II2025
2025-07-10HISTOSONICS, INC.$12,845Research paymentCash or cash equivalentThe HistoSonics Edison System for treatment of primary solid renal tumors using histotripsy2025
2025-07-09Stryker Corporation$5,063Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTEREVCORE FOR IN STENT THROMBOSIS (REVIT)2025
2025-07-09Stryker Corporation$5,063Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-07-08Luminex Corporation$2,424HonorariaIn-kind items and servicesLIAISON PLEX Device, Device2025
2025-07-03Karyopharm Therapeutics Inc.$6,030Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-07-03Karyopharm Therapeutics Inc.$4,236Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-07-03Karyopharm Therapeutics Inc.$2,073Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-07-03Karyopharm Therapeutics Inc.$473Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-07-03Karyopharm Therapeutics Inc.$198Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-07-03Karyopharm Therapeutics Inc.$99Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-07-03Karyopharm Therapeutics Inc.$65Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-07-01PFIZER INC.$27,215Research paymentCash or cash equivalentA PHASE 1 RANDOMIZED OPENLABEL 3PERIOD CROSSOVER SINGLEDOSE 2PART STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE EFFEC2025
2025-06-30Stryker Corporation$1,929Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,929Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,929Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,929Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,929Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,929Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,929Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,929Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,929Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,550Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PEERLESS II STUDY2025
2025-06-30Stryker Corporation$1,350Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,350Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,350Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,350Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,350Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,350Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,350Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,350Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$1,350Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$955Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$955Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$955Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$955Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$955Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$955Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$955Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$955Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$955Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$859Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PROTRIEVE PROTECTOR STUDY (PROTECTOR)2025
2025-06-30Stryker Corporation$826Research paymentCash or cash equivalentFLOWTRIEVER CATHETER, S Device, VTETHE PEERLESS II STUDY2025
2025-06-27E.R. Squibb & Sons, L.L.C.$79,067Research paymentCash or cash equivalentA Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibro2025
2025-06-26Novartis Pharmaceuticals Corporation$106,112Research paymentIn-kind items and servicesKISQALI Drug, OncologyA Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patients Selection for Moderate to Hig2025
2025-06-25Eisai Inc.$125EducationCash or cash equivalent2025
2025-06-18GE HEALTHCARE$41,440Research paymentCash or cash equivalentPoint of Care Lung Ultrasound Examination in Patients with Shortness of Breath2025
2025-06-11Alexion Pharmaceuticals, Inc.$109Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-06-11Abbott Laboratories$45Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-06-10Incyte Corporation$5,000EducationCash or cash equivalent2025
2025-06-03Siemens Medical Solutions USA, Inc.$189,280Research paymentIn-kind items and servicesBiograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR)Personalized task-based respiratory motion correction for low-dose PET-CT2025
2025-06-02Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-06-02Karyopharm Therapeutics Inc.$750Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-06-02Karyopharm Therapeutics Inc.$750Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-06-02Karyopharm Therapeutics Inc.$750Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-06-02Karyopharm Therapeutics Inc.$400Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-05-30Shockwave Medical, Inc$1,730Research paymentCash or cash equivalentEquity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease2025
2025-05-30Shockwave Medical, Inc$500Research paymentCash or cash equivalentEquity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease2025
2025-05-29Siemens Medical Solutions USA, Inc.$5,400GrantIn-kind items and servicesAutomated Blood Coagulation Analyzer CS-2500 Device, DX - Diagnostics incl. all products and services2025
2025-05-27Alexion Pharmaceuticals, Inc.$333Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-23Incyte Corporation$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentMONJUVI Drug, Oncology2025
2025-05-22Genentech USA, Inc.$15,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentPhesgo Biological, BioOncology2025
2025-05-21PFIZER INC.$20,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-21ARRAY BIOPHARMA INC$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-21PFIZER INC.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-21PFIZER INC.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-21PFIZER INC.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-21PFIZER INC.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-20Ambu Inc.$3,095GrantCash or cash equivalent2025
2025-05-14Alexion Pharmaceuticals, Inc.$379Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-08ABBVIE INC.$135,647Research paymentIn-kind items and servicesELAHERE Drug, ONCOLOGYA randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positi2025
2025-05-05Karyopharm Therapeutics Inc.$4,236Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-05-05Karyopharm Therapeutics Inc.$3,421Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-05-05Karyopharm Therapeutics Inc.$2,856Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-05-05Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-05-05Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-05-05Karyopharm Therapeutics Inc.$473Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-05-05Karyopharm Therapeutics Inc.$400Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-05-05Karyopharm Therapeutics Inc.$400Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-05-02Siemens Medical Solutions USA, Inc.$504Debt forgivenessCash or cash equivalent2025
2025-05-01Alexion Pharmaceuticals, Inc.$821Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-01Alexion Pharmaceuticals, Inc.$745Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-01Alexion Pharmaceuticals, Inc.$303Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-01Alexion Pharmaceuticals, Inc.$111Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-01Alexion Pharmaceuticals, Inc.$70Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-04-29Alexion Pharmaceuticals, Inc.$25Charitable ContributionCash or cash equivalent2025
2025-04-28KLS-Martin L.P.$8,264Debt forgivenessCash or cash equivalentIPS, IMPLANT, CRANIAL, 00089, CP TITANIUM, QTY: 001 EA Device, Osteosynthesis2025
2025-04-28KLS-Martin L.P.$1,975Debt forgivenessCash or cash equivalentIPS, SUPPLEMENTAL MODEL, FULL, 00007, QTY: 001 EA Device, Osteosynthesis2025
2025-04-25National Marrow Donor Program$17,265Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-04-22Medical Device Business Services, Inc.$2,260GrantCash or cash equivalent2025
2025-04-16Novartis Pharmaceuticals Corporation$7,940Research paymentCash or cash equivalentKISQALI Drug, OncologyRibociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence2025
2025-04-14BioXcel Therapeutics, Inc.$14,621Research paymentCash or cash equivalentBXCL-701-2012025
2025-04-09Abbott Laboratories$124Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-04-09Abbott Laboratories$45Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-04-07Karyopharm Therapeutics Inc.$4,236Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-04-07Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-04-07Shockwave Medical, Inc$1,500Research paymentCash or cash equivalentEquity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease2025
2025-04-07Karyopharm Therapeutics Inc.$400Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-04-04TransMedics, Inc.$18,689Research paymentCash or cash equivalentOrgan Care System Device, DeviceOCSHEART-OHP-II2025
2025-04-02Alexion Pharmaceuticals, Inc.$140Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-03-19PFIZER INC.$17,033Research paymentCash or cash equivalentPRE CLINICAL2025
2025-03-12Eisai Inc.$5,000GrantCash or cash equivalentLenvima Drug, Oncology2025
2025-03-11Zimmer Biomet Holdings, Inc.$108GrantCash or cash equivalent2025
2025-03-07Shockwave Medical, Inc$2,030Research paymentCash or cash equivalentEquity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease2025
2025-03-06Karyopharm Therapeutics Inc.$17,716Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-03-06Karyopharm Therapeutics Inc.$6,701Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-03-06Karyopharm Therapeutics Inc.$2,017Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-03-06Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-03-06Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025
2025-03-06Karyopharm Therapeutics Inc.$1,788Research paymentCash or cash equivalentXPOVIO Drug, OncologyA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis2025

The latest 200 records of 234.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

South Central Connecticut Planning RegionNew Haven city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.

MeasurePlace (city or town)
New Haven, CT
County
South Central Connecticut Planning Region, CT
State
Connecticut
Population B01003134,349570,5983,624,508
Population, 2020 census P1134,023-3,605,944
Median age B0100231.940.241.1
Under 18 B0100121.3%19.6%20.2%
65 and over B0100111.8%18.6%18.5%
Households B1100154,773230,6731,434,007
Foreign born B0500218.0%13.7%15.7%
Median household income B19013$56,851$88,197$95,781
Median family income B19113$68,668$115,384$122,706
Per capita income B19301$36,242$49,766$55,915
Poverty rate B1700123.9%11.4%10.0%
Unemployment rate B230258.4%6.0%5.6%
Civilian labor force B2302569,528307,6071,959,490
Mean commute (minutes) B0801321.523.526.5
Bachelor's degree or higher B1500338.9%42.0%42.5%
Housing units B2500160,333248,2671,541,822
Owner-occupied B2500328.4%60.5%66.5%
Renters B2500371.6%39.5%33.5%
Median home value B25077$287,100$353,100$366,900
Median gross rent B25064$1,488$1,525$1,488
White, not Hispanic B0300230.0%58.5%61.9%
Black B0300227.6%13.0%9.8%
Hispanic or Latino B0300231.0%19.5%18.3%
Asian B030025.2%4.5%4.7%
American Indian and Alaska Native B030020.2%0.1%0.1%

Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); Unemployment rate: 4.7% in Sep 2016 to 5.1% in Sep 2026; low 3.1%, high 11.9% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.